Last reviewed · How we verify

Staph Aureus Traumatic Skin Lesion Infection — Treatment Landscape & Competitive Intelligence

Staph Aureus Traumatic Skin Lesion Infection (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Staph Aureus Traumatic Skin Lesion Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Bactroban MUPIROCIN GSK RNA Synthetase Inhibitor Antibacterial Isoleucine--tRNA ligase, cytoplasmic 1987-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. GSK · 1 drug in Staph Aureus Traumatic Skin Lesion Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Staph Aureus Traumatic Skin Lesion Infection:

Cite this brief

Drug Landscape (2026). Staph Aureus Traumatic Skin Lesion Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staph-aureus-traumatic-skin-lesion-infection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing